<DOC>
	<DOC>NCT01474681</DOC>
	<brief_summary>This study is designed to evaluate the safety and tolerability of using HSC835 in patients with hematological malignancies.</brief_summary>
	<brief_title>Safety and Tolerability of HSC835 in Patients With Hematological Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Mantle-Cell</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<criteria>Patients with a diagnosis that qualifies them for a DUCBT Absence of recent active mold infection Adequate organ function Availability of eligible donor material Pregnancy or breastfeeding women and women of childbearing potential unless two acceptable forms of contraception are being used Human immunodeficiency virus (HIV) infection Active infection Extensive prior chemotherapy Prior myeloablative allotransplantation or autologous transplant.</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hematologic malignancies</keyword>
	<keyword>leukemia</keyword>
	<keyword>lymphoma</keyword>
</DOC>